• Home
  • About
    • Group CEO
    • Management Team
    • Supervisory Board
    • Scientific Advisory Board
    • Affiliates
    • R&D Partnerships
    • Distributors
    • Quality Standards
    • Location
  • Services
    • Proteomics
    • Genomics Transcriptomics
    • Flow Cytometry
    • Assay Development
    • Monoclonal Antibodies
    • Biobanking
    • OLINK Services
    • Biomarker Data Analyses
  • R&D
  • Products
    • NEUROLINCS
    • FIMICS
    • BIOPRED
    • IVD Products
    • ELISA Kits
    • Recombinant Proteins
    • Monoclonal Abodies
    • Clinical Samples
    • Your Customized Kit
  • Quality
  • Investors
    • Financial Management
    • Financial Data
    • Shareholders
  • Media
    • Press Releases
    • Media News
    • Newsletters
    • Posts
    • All Media
  • Careers
Contact
Firalis
  • Home
  • About
  • Services
  • Products
  • R&D
  • Quality
  • Investors
  • Media

FIMICS PANEL
a long non-coding RNA panel to better characterize cardiac disorders and toxicities

FIMICS is the result of years of research on cardiac lncRNAs in cooperation with several research institutes of excellence and the collaboration with Celemics, a Seoul based biotech company specialized in Next-Generation Sequencing solutions. LncRNAs are a highly tissue specific family of RNA opening new horizons for diagnostic and therapeutic applications in the cardiovascular field. Identification of cardiac enriched lncRNAs were performed using deep sequencing human cardiac biopsies of failing and control hearts. Expression levels were compared to 12 others organs to select cardiac enriched lncRNAs.

A total of 3233 lncRNAs including 1036 novel lncRNAs never previously described were identified and included into FiMICS panel. Detection and precise quantification of these cardiac enriched lncRNAs in peripheral blood using FiMICS provide first-class results to the final users and opens new ways for therapeutics and precision medicine tools for diverse primary and secondary cardiac diseases, cardiac toxicities and drug development.

Features & Benefits

  • First in class test for the measurement of cardiac enriched lncRNA in peripheral blood

  • Proprietary list of cardiac enriched lncRNAs coming from years of research

  • More than 55.000 capture probes for high coverage of lncRNAs sequences

  • Investigation of a novel class of biomarkers/therapeutic targets

  • Get direct insight of heart condition using blood without needing cardiac biopsies.

  • Characterization of patients with diverse cardiac disorders and toxicities

High detection rate of cardiac enriched lncRNAs in peripheral blood and first-class performaces

Fimics Firalis

Fimics Firalis

FiMICS lncRNAs analysis workflow: sample to results

Fimics Firalis

  • Non-invasive samples to investigate cardiac enriched lncRNAs

  • PAXgene and cardiac tissue already validated.

  • Excellent analytical performance with high reproducibility of the results

  • High sensitivity with ~2800 lncRNAs detected in PAXgene samples over 3233 (FPKM>0,1)

  • Plasma samples in validation process with more than 1500 lncRNAs detected (FPKM>0,1)

available here : FiMICS Datasheet

 

We support our clients to optimize each step of their biomarker research and development programs, from concept to regulatory qualification for all international markets.

Our team has significant experience in the regulatory qualification of biomarker-based panels and in vitro diagnostics (IVD) tools in Europe (development and submission for CE marked kits) and in the US (IVD and LTD kits) according to EMA and FDA guidelines.

Use our expertise in analytics, regulatory strategy, and in biospecimens solutions for comprehensive support across your research needs:

  • Design of biomarker program and analytical development

  • Planning and study design

  • Development of Standard Operating Procedures (SOPs)

  • Regulatory support: preparing dossiers and opinion meeting

  • Biomarker regulatory qualification for IVD development

 

Contact us at sales@firalis.com to get further details and to discuss your projects.

 

Contact Firalis

Firalis Group

© Copyright 2020 all rights reserved. 

The company logos, products and service marks are trademarks or registered trademarks of Firalis.

-----------------------------------------------------------------------------------------------------------------------

Information addressed to health professionals. The products presented on this site are for professional use only and, where applicable, comply with the requirements of the IVD Directive 98/79 / EC. Instructions for use must be consulted before using these products.

-----------------------------------------------------------------------------------------------------------------------

Headquarter : 17 Rue du Fort 68330 Huningue FRANCE